Volumetric Analysis in the Assessment of Therapy Response by CT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00582751

Enrollment

Registered

2007-12-28

Start date

2007-11-30

Completion date

2010-11-30

Last updated

2010-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Diseases

Keywords

Volumetric Analysis, Multiple Diseases

Brief summary

To compare the volumetric response achieved using semi-automated computer techniques with the uni-dimensional (RECIST) and bi-dimensional (WHO) criteria as part of clinical trials running at MSKCC, testing new agents for different types of solid tumors.

Detailed description

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Registered and being treated on one of the following therapeutic protocols: 06-043, 07-052, 07-057, 07-112, 07-116, 08-093, and 08-054 * Have at least one measurable lesion\* as per RECIST criteria situated in lung, liver or lymph node meeting RECIST criteria noted on a baseline CT scan. * Baseline\*\* and at least one follow-up CT scan to likely to be obtained at an MSKCC facility * All patients must be \> or = to 18 years old * The measurable lesions are metastatic in the liver, lung and lymph nodes. The algorithms do not distinguish between primary and metastatic disease, therefore, in selected cases, a primary lesion such as in the liver or lung may also be assessed. * Baseline CT are prefer but if not able to obtain for volumetric reconstructions follow up studies will still be use for other objectives if the study.

Exclusion criteria

* Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
To compare volumetric response achieved using semi-automated computer techniques with the uni-dimensional (RECIST) and bi-dimensional (WHO) criteria as part of clinical trials running at MSKCC, testing new agents for different types of solid tumors.	1 year

Countries

United States

Outcome results